HOSSAM M. HASSAN | Pharmaceutical Sciences | Best Researcher Award

Prof. Dr. HOSSAM M. HASSAN | Pharmaceutical Sciences | Best Researcher Award

prof.Dr. Hossam M. Hassan , College of Pharmacy, University of Kut,Iraq

Dr. Hossam Mokhtar Hassan 🇪🇬 is an esteemed Associate Professor of Pharmacognosy at Nahda University and Beni-Suef University, Egypt 🧪. With a Ph.D. in Pharmaceutical Sciences and postdoctoral training at UCSD’s Scripps Institute 🌊, his expertise lies in natural product chemistry, marine pharmacognosy, and phytotherapy 🌿. He currently serves as Vice-Dean for Postgraduate Affairs and General Manager of the Central Research Lab at NUB 🧫. A dedicated educator and researcher, he has received multiple accolades 🏆 and remains active in scientific societies, pushing the boundaries of drug discovery from natural and marine sources 🔬.

Professional Profile:

Scopus

🎓 Education & Experience 

🎓 Education:

  • 🧪 Ph.D. in Pharmaceutical Sciences, University of Louisiana & Beni-Suef University, 2010

  • 🌿 M.Sc. in Pharmacognosy, Cairo University, 2006

  • 💊 B.Sc. in Pharmaceutical Sciences (Honors), Cairo University, 2000

  • 🌊 Postdoc at Scripps Institute of Oceanography, UCSD, 2013-2014

💼 Experience:

  • 🏛️ Vice-Dean for Postgraduate Affairs, Faculty of Pharmacy, NUB (2019–Present)

  • 👨‍🏫 Associate Professor, Nahda & Beni-Suef Universities (2016–Present)

  • 🧪 General Manager, Central Research Lab, NUB (2017–Present)

📈 Professional Development 

Dr. Hassan has continually honed his skills through international fellowships and academic training 🧳. He has mastered advanced techniques such as NMR, HPLC, LC/MS, GC/MS, and molecular docking for natural product analysis 🔬🧫. His scientific capabilities span pharmacophore modeling, phytochemistry, and marine bioprospecting 🌊🌱. He has also developed leadership skills as a strategic planning team leader at NUB 🗂️, with training in effective teaching, decision-making, communication, and problem-solving 🎯🗣️. His active memberships in the American Society of Pharmacognosy and the Egyptian Syndicate of Pharmacists reflect his commitment to global scientific communities 🌍📚.

🔍 Research Focus Category 

Dr. Hassan’s research is centered on natural product drug discovery, especially from marine and plant-derived sources 🌊🌿. He isolates bioactive compounds from symbiotic bacteria, fungi, and medicinal plants to explore their pharmacological potential 💊. His work involves biotransformation, chemical derivatization, and 3D-QSAR studies for structure–activity relationships 🧪🧬. His expertise in phytochemistry and marine pharmacognosy contributes to identifying novel therapeutic agents against microbial infections, cancer, and fertility disorders 🔬👨‍⚕️. Integrating cutting-edge analytical and modeling techniques, he aims to harness nature’s biodiversity for modern medicine 🌍🧫.

🏆 Awards & Honors 

  • 🏅 Best Master’s Thesis, Faculty of Pharmacy, Cairo University, 2006

  • 🏆 Armor of Excellence, Egyptian Pharmacists Syndicate, 2007

  • 🏆 Armor of Excellence, Egyptian Pharmacists Syndicate, 2012

  • 🎓 Best Ph.D. Thesis in Pharmacognosy, All Egyptian Pharmacy Faculties, 2012

Publication Top Notes:

1. Pachycladins A–E: Eunicellin-Based Diterpenoids

Hassan HM, Khanfar MA, Elnagar AY, Mohammed R, Shaala LA, Youssef DT, Hifnawy MS, El Sayed KA. Pachycladins A–E, prostate cancer invasion and migration inhibitory Eunicellin-based diterpenoids from the Red Sea soft coral Cladiella pachyclados. J Nat Prod. 2010; 73(5):848–853.
https://doi.org/10.1021/np900858m

🔬 Summary:
This study reports the isolation of five new Eunicellin-based diterpenoids, named Pachycladins A–E, from the Red Sea soft coral Cladiella pachyclados. These compounds were shown to inhibit the migration and invasion of prostate cancer cells, indicating promising anticancer potential through marine natural product chemistry.

2. 3D-QSAR of Semisynthetic Eunicellin Diterpenoids

Hassan HM, Elnagar AY, Khanfar MA, Sallam A, Mohammed R, Shaala LA, Youssef DT, Hifnawy MS, El Sayed KA. Design and 3D-quantitative structure-activity relationship of semisynthetic eunicellin-based diterpenoids as prostate cancer migration and invasion inhibitors. Eur J Med Chem. 2011; 46(4):1122–1130.
https://doi.org/10.1016/j.ejmech.2011.01.055

🧪 Summary:
The paper explores the design and synthesis of semisynthetic derivatives of eunicellin-based diterpenoids and develops a 3D-QSAR model to evaluate their anticancer activity. These analogs demonstrated enhanced inhibition of prostate cancer cell migration and invasion, highlighting their potential for further drug development.

3. Semisynthetic Sarcophine Derivatives as Anticancer Agents

Hassan HM, Sallam AA, Mohammed R, Hifnawy MS, Youssef DT, El Sayed KA. Semisynthetic analogues of the marine cembranoid sarcophine as prostate and breast cancer migration inhibitors. Bioorg Med Chem. 2011; 19(16):4928–4934.
https://doi.org/10.1016/j.bmc.2011.06.073

🧬 Summary:
This study details the synthesis of analogues of sarcophine, a marine cembranoid, and evaluates their ability to inhibit migration in prostate and breast cancer cell lines. Several derivatives showed strong bioactivity, offering new leads in anticancer drug discovery.

4. Decorosides A and B: Cytotoxic Flavonoid Glycosides

Mostafa ER, Hossam MH, El-Shaimaa AA, Marcel J, Rainer E. Decorosides A and B, cytotoxic flavonoid glycosides from the leaves of Rhododendron decorum. Nat Prod Commun. 2014; 9(4):473–476.
https://doi.org/10.1177/1934578X1400900408

🌿 Summary:
The article reports the isolation of two new flavonoid glycosides—Decorosides A and B—from Rhododendron decorum. Both compounds exhibited cytotoxic effects, contributing to the growing interest in plant-derived anticancer agents.

5. Salinamide F: A Marine-Derived Depsipeptide Antibiotic

Hossam MH, David D, Kyoung HJ, Richard HE, William F. Salinamide F, new depsipeptide antibiotic and inhibitor of bacterial RNA polymerase from a marine-derived Streptomyces sp. J Antibiot. 2015; 68(3):206–210.
https://doi.org/10.1038/ja.2014.127

🧫 Summary:
This paper describes the discovery of Salinamide F, a novel depsipeptide isolated from Streptomyces sp.. The compound functions as a potent inhibitor of bacterial RNA polymerase, demonstrating promise as a new class of antibiotic against resistant bacteria.

6. Bioactivity of Pulicaria undulata Metabolites

Taha AH, Sayed AE-T, Hossam MH, Mona HH. Cytotoxic and antioxidant activities of secondary metabolites from Pulicaria undulata. Int J Pharm Pharm Sci. 2016; 8(9):150–155.
https://innovareacademics.in/journals/index.php/ijpps/article/view/13208

🌼 Summary:
The study investigates secondary metabolites from Pulicaria undulata, demonstrating both cytotoxic and antioxidant activities. It highlights the plant’s potential as a natural source of therapeutic agents targeting oxidative stress and cancer.

Conclusion:

Prof. Dr. Hossam M. Hassan exemplifies the qualities of a Best Researcher Award recipient through:

  • Innovative scientific contributions in natural products and pharmaceutical chemistry,

  • Strategic academic leadership and international collaboration,

  • Sustained impact on public health-oriented drug discovery.

His work not only advances science but also addresses critical global health challenges such as cancer, antibiotic resistance, and oxidative stress disorders.

Assist. Prof. Dr. Mohamed skiba | Pharmaceutics Award | Best Innovation Award

Assist. Prof. Dr. Mohamed skiba | Pharmaceutics Award | Best Innovation Award

Assist. Prof. Dr. Mohamed skiba, University of rouen, France

Dr. Mohamed Skiba, is a French national and a distinguished pharmaceutical scientist. He is a lecturer at the Faculty of Medicine and Pharmacy in Rouen, where he leads the Pharmaceutical Team within the Galenic Group. Dr. Skiba earned his Ph.D. in Pharmaceutical Sciences from the University of Paris XI in 1994 and has been active in pharmaceutical research since 1990, focusing on cyclodextrin and drug vectorization. With over 140 international publications, 80 patents, and numerous contributions to books and congresses, he is a recognized expert in pharmaceutical technology. Dr. Skiba is also an active member of several scientific societies, including the French Society of Chemistry and the French Association of Teachers of Technological Pharmacy. He is fluent in French, English, and Arabic.

Professional Profile:

Orcid

Suitability for Best Innovation Award: Dr. Mohamed SKIBA

Dr. Mohamed Skiba’s extensive work in pharmaceutical sciences, particularly his research in drug formulation and cyclodextrin technologies, positions him as a strong candidate for the Best Innovation Award. His innovations, reflected in his numerous patents and publications, highlight his ability to drive pharmaceutical advancements with real-world applications. His leadership in academic and research institutions further amplifies his impact, making him a deserving recipient of this prestigious award.

🎓Education:

Dr. Mohamed Skiba holds a Ph.D. in Pharmaceutical Sciences, which he earned in 1994 from the University of Paris XI, Southern Paris. His academic journey also includes a Diploma of Thorough Studies in Pharmacotechnology and Biopharmacy (1990) from the University of Paris XI in Châtenay-Malabry. In 1990, he obtained a Diploma in Veterinary Pharmaceuticals from the Faculty of Pharmacy, University of Clermont-Ferrand I. Additionally, Dr. Skiba completed advanced studies in pharmacology and electrophysiology with a Control of Research degree from the University of Poitiers in 1989. He also pursued studies in patent rights at the Faculty of Orsay, University of Paris-South, enriching his expertise in pharmaceutical and intellectual property matters.

🏢Work Experience:

Dr. Mohamed Skiba has been a lecturer at the Faculty of Medicine and Pharmacy, University of Rouen, France, since 1998. In this role, he teaches courses in galenic and industrial galenic pharmacy to both undergraduate and graduate students, while also leading the Pharmaceutical Team within the Galenic Group. His professional experience includes serving as a trainee at the Central Pharmacy of the Hospitals of Paris (PCH) and working as an Associated Attaché in Toxicology and Clinical Pharmacology at the Hospital of Corbeil-Essonnes, further enhancing his expertise in pharmaceutical technology and clinical applications.

🏅Awards & Recognition:

Dr. Mohamed Skiba is a prolific contributor to the field of pharmaceutical technology, holding over 80 patents that highlight his innovative work. He has authored 140 international publications and contributed to 9 book chapters, making significant scholarly impacts. Additionally, Dr. Skiba has presented 71 communications at prestigious scientific congresses, sharing his research and advancements with the global scientific community.

🔬Research Focus:

Dr. Skiba’s research primarily centers on pharmaceutical technology, with a particular focus on cyclodextrin and drug vectorization. His work involves improving drug delivery systems, studying bio-polymeric materials, and developing innovative pharmaceutical formulations. He has been involved in numerous pharmaceutical research projects since 1990, contributing to the advancement of drug delivery and formulation technologies.

Publication Top Notes:

  • Powder Self-Emulsifying Drug Delivery System for Mitotane: In Vitro and In Vivo Evaluation
  • In vitro dissolution of encapsulated or dispersed vitamin E and cholesterol is correlated with preservation of refrigerated ovine sperm
  • Exploring the Therapeutic Potential of Algerian Propolis: GC/MS Profiling, Protective Inclusion Complex, and In Silico Evaluation Against SARS‐CoV‐2 Main Proteases
  • Development of a Novel Cyclodextrin–Chitosan Polymer for an Efficient Removal of Pharmaceutical Contaminants in Aqueous Solution

 

 

Prof. Franciska Erdo | Drug delivery Award | Best Researcher Award

Prof. Franciska Erdo | Drug delivery Award | Best Researcher Award

Prof. Franciska Erdo , Pázmány Péter Catholic University , Hungary

Franciska Vidáné Dr. Erdő, born on May 28, 1964, in Budapest, is a distinguished full professor and lab head at Pázmány Péter Catholic University, Faculty of Information Technology and Bionics. She holds a PhD in pharmacology from Semmelweis University and has extensive experience in both academic and research institutions, including the University of Tours, Charité Medizinische Universität in Berlin, and the Max-Planck Institute in Cologne. Her research focuses on drug research and development, evidenced by her numerous fellowships and scholarships. She has supervised over 31 graduate students and postdoctoral fellows and has been recognized for her teaching excellence. Dr. Erdő has also contributed significantly to scientific literature and education, particularly in the fields of molecular bionics and biomedical innovation.

Professional Profile:

Orcid

Education:

Franciska Vidáné Dr. Erdő earned her MSc in Pharmacy from Semmelweis University in 1987, graduating with top grades. She continued her education at the same institution, achieving a University Doctor degree in Pharmacology with summa cum laude honors in 1994. In 1997, she completed her PhD in Pharmacology, also with summa cum laude distinction, at Semmelweis University, Faculty of Pharmacy. Most recently, in 2019, she received her habilitation from Pázmány Péter Catholic University, Faculty of Information Technology and Bionics.

Work Experience:

Franciska Vidáné Dr. Erdő has held numerous esteemed positions throughout her career. Since 2024, she has been serving as a Full Professor and Lab Head at Pázmány Péter Catholic University, Faculty of Information Technology and Bionics. Prior to this, from 2019 to 2024, she was an Associate Professor and Lab Head at the same institution. She was also a Guest Researcher at the University of Tours, France, in 2022. From 2014 to 2019, she worked as a Senior Research Fellow and Lab Head at Pázmány Péter Catholic University. Her earlier roles include serving as a Senior Research Fellow and Lab Head at SOLVO Biotechnology from 2007 to 2014, and holding a scientific scholarship at Charité Medizinische Universität in Berlin, Germany, from 2005 to 2006. She also worked as a Senior Research Fellow at IVAX Drug Research Institute from 2003 to 2007 and held a Max Planck Fellowship at the Max-Planck Institute für neurologische Forschung in Cologne, Germany, from 2000 to 2003. Her earlier positions include Senior Research Fellow roles at Sanofi-Synthelabo Chinoin from 1997 to 2000 and Biorex R&D Co. from 1995 to 1997. She began her career as a Research Fellow at the Institute for Drug Research from 1990 to 1995 and as a Junior Research Fellow at the same institute from 1987 to 1990.

Publication Top Notes:

1.Fluid Dynamics Optimization of Microfluidic Diffusion Systems for Assessment of Transdermal Drug Delivery: An Experimental and Simulation Study

  • Journal: Scientia Pharmaceutica
  • Publication Date: June 2024

2. Progress in Topical and Transdermal Drug Delivery Research—Focus on Nanoformulations

  • Journal: Pharmaceutics
  • Publication Date: June 2024

3. Transdermal Delivery of α-Aminophosphonates as Semisolid Formulations—An In Vitro-Ex Vivo Study

  • Journal: Pharmaceutics
  • Publication Date: May 2023